Can semaglutide help with heart failure?

For heart failure with preserved ejection fraction (HFpEF), the most common form of heart failure in overweight adults over 50, semaglutide shows meaningful symptom improvement. The STEP-HFpEF trial demonstrated that semaglutide reduced Kansas City Cardiomyopathy Questionnaire scores (a quality-of-life measure) and six-minute walk distance compared to placebo in patients with HFpEF and obesity. The structural mechanism is sensible: visceral fat reduction reduces pericardial fat and cardiac filling pressures, improving diastolic function directly.

Mortality data for HFpEF specifically remains an active area of investigation, with larger trials underway. The SELECT trial also showed that semaglutide did not worsen outcomes in the subset of patients with heart failure, providing cardiovascular safety reassurance in this population. For men with HFpEF who are overweight, semaglutide represents a pharmacological tool that simultaneously addresses weight, blood pressure, inflammation, and symptoms, a combination not available in any other single agent. The conversation with your cardiologist about GLP-1 therapy in this context is well-supported by current evidence. (Kosiborod et al., NEJM, 2023)

Cardiologist's calibrated position, Promising (2) for symptom improvement and quality of life in HFpEF with obesity. Early (3) for mortality reduction as a primary HFpEF indication.

What to do: If you have HFpEF and are overweight, ask your cardiologist specifically about the STEP-HFpEF trial and whether semaglutide is appropriate in the context of your current heart failure management.

For the full picture, read The Drug That Surprised Cardiologists.